Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
| Descriptor ID |
D015452
|
| MeSH Number(s) |
C04.557.337.428.600.600 C15.604.515.560.600.600 C20.683.515.528.600.600
|
| Concept/Terms |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Precursor B Cell Lymphoblastic Leukemia Lymphoma
- Pre B-ALL
- Pre-B ALL
- Pre B ALL
- Precursor B-Cell Lymphoblastic Leukemia
- Precursor B Cell Lymphoblastic Leukemia
- Precursor B-Cell Lymphoblastic Lymphoma
- Precursor B Cell Lymphoblastic Lymphoma
- Leukemia, Pre-B-Cell
- Leukemia, Pre B Cell
- Leukemias, Pre-B-Cell
- Pre-B-Cell Leukemias
- Pre-B-Cell Leukemia
- Pre B Cell Leukemia
|
Below are MeSH descriptors whose meaning is more general than "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma".
Below are MeSH descriptors whose meaning is more specific than "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma".
This graph shows the total number of publications written about "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" by people in this website by year, and whether "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 3 | 1 | 4 |
| 2015 | 5 | 0 | 5 |
| 2016 | 4 | 0 | 4 |
| 2017 | 4 | 1 | 5 |
| 2018 | 8 | 0 | 8 |
| 2019 | 5 | 2 | 7 |
| 2020 | 3 | 0 | 3 |
| 2021 | 6 | 0 | 6 |
| 2022 | 1 | 0 | 1 |
| 2023 | 8 | 1 | 9 |
| 2024 | 3 | 2 | 5 |
| 2025 | 12 | 0 | 12 |
| 2026 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" by people in Profiles.
-
CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review. Blood Adv. 2026 May 26; 10(10):3467-3479.
-
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood. 2026 Apr 23; 147(17):2011-2017.
-
Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia. Blood Adv. 2026 Mar 10; 10(5):1700-1712.
-
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era. Hematology Am Soc Hematol Educ Program. 2025 Dec 05; 2025(1):229-235.
-
Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec; 23(12).
-
Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis. Blood Adv. 2025 Nov 11; 9(21):5489-5500.
-
Decoding the genetic complexity in a pediatric case of B-ALL through long-read genomic sequencing and RNA sequencing. Cancer Genet. 2025 Nov; 298-299:274-279.
-
Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group. Transplant Cell Ther. 2026 Mar; 32(3):261-276.
-
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025 Oct 28; 9(20):5249-5262.
-
Genome-wide association study of childhood B-cell acute lymphoblastic leukemia reveals novel African ancestry-specific susceptibility loci. Nat Commun. 2025 Oct 22; 16(1):8974.